Loading...
The Pfizer (BNT162b2) and Oxford/AstraZeneca (ChAdOx1) vaccines have shown remarkable efficacy in phase 3 trials as well as effectiveness in mass vaccination (NEJM JW Infect Dis Apr 2021 and N Engl J Med 2021 Feb 24; [e-pub]). But how effective are these vaccines under the British vaccination policy, which has advised delaying the second dose to allow broader immunization in regions with limited supplies?
Vasileiou et al. performed a prospective cohort study in 99% of the Scottish population using data on vaccination status, SARS-CoV-2 PCR results, and hospital admissions between December 8, 2020, and Feb 22, 2021. During this period, >1.3 million Scottish residents (30% of the adult population) received one dose of either the BNT162b2 or th…